CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
CG Oncology reported positive Phase 2 results from the CORE-008 Cohort CX trial, evaluating intravesical cretostimogene combined with gemcitabine in high-risk non-muscle invasive bladder cancer patients. The study showed high complete response rates of 85.7% in the intent-to-treat population and 92.3% in the efficacy-evaluable population, with high-grade event-free survival of 96.0% at 3 months and 89.5% at 6 months.
Key figures
- Drug Name
- cretostimogene grenadenorepvec
- Phase Of Trial
- Phase 2
- Cr rate itt
- 85.7%
- Bcp exposed pct
- 65.6%
- Deaths reported
- 0
- Hg efs 3 months
- 96.0%
- Hg efs 6 months
- 89.5%
- Grade 3 plus traes
- 0
- Bcp unresponsive pct
- 34.5%
- Median follow up months
- 6.6
- Cr rate efficacy evaluable
- 92.3%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.